Zymeworks ZYME
NASDAQ ZYME
$29.19 -0.71 (-2.37%)
As of: Sep 4, 2026 · 3:59 PM EDT

Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026)

Zymeworks (ZYME) posted Total Non-Current Liabilities of $314.3 million for Q1 2026, up 304.32% sequentially from $77.7 million in Q4 2025, and up 215.3% YoY from $99.7 million in Q1 2025.

Analysis

Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Zymeworks has reported Total Non-Current Liabilities for 6 years, with the latest figure at $314.3 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 215.3% year-over-year to $314.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.3 million (up 215.3% YoY) and the FY2025 annual result came in at $77.7 million, down 37.0% from the prior year.
  • Total Non-Current Liabilities improved to $314.3 million in Q1 2026 per ZYME's latest filing, from $77.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $314.3 million in Q1 2026 and troughed at $73.1 million in Q2 2025.
  • A 5-year average of $126.5 million and a median of $117.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities tumbled 37.0% in 2025, then jumped 215.3% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $154.1 million in 2022, then dropped by 25.79% to $114.4 million in 2023, then advanced by 7.89% to $123.4 million in 2024, then sank by 37.0% to $77.7 million in 2025, then jumped by 304.32% to $314.3 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $314.3 million, $77.7 million, and $76.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Zymeworks 2.13 Bn 1.86 Bn - 316.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 316.32 Mn
Mar 31, 2026 314.35 Mn
Dec 31, 2025 77.75 Mn
Sep 30, 2025 76.93 Mn
Jun 30, 2025 73.05 Mn
Mar 31, 2025 99.70 Mn
Dec 31, 2024 123.40 Mn
Sep 30, 2024 119.25 Mn
Jun 30, 2024 108.24 Mn
Mar 31, 2024 114.16 Mn
Dec 31, 2023 114.37 Mn
Sep 30, 2023 130.16 Mn
Jun 30, 2023 149.54 Mn
Mar 31, 2023 123.61 Mn
Dec 31, 2022 152.67 Mn
Sep 30, 2022 117.57 Mn
Dec 31, 2021 132.28 Mn